Free Trial

19,302 Shares in Ingevity Co. (NYSE:NGVT) Purchased by Susquehanna Fundamental Investments LLC

Ingevity logo with Basic Materials background

Susquehanna Fundamental Investments LLC acquired a new position in shares of Ingevity Co. (NYSE:NGVT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 19,302 shares of the company's stock, valued at approximately $787,000. Susquehanna Fundamental Investments LLC owned 0.05% of Ingevity at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NGVT. American Century Companies Inc. increased its stake in Ingevity by 37.7% in the fourth quarter. American Century Companies Inc. now owns 1,457,365 shares of the company's stock valued at $59,388,000 after acquiring an additional 398,800 shares during the last quarter. Royce & Associates LP grew its stake in Ingevity by 22.4% during the 4th quarter. Royce & Associates LP now owns 1,142,598 shares of the company's stock valued at $46,561,000 after purchasing an additional 208,921 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Ingevity during the fourth quarter valued at $4,882,000. Wellington Management Group LLP increased its stake in Ingevity by 5.4% during the fourth quarter. Wellington Management Group LLP now owns 2,239,970 shares of the company's stock worth $91,279,000 after acquiring an additional 115,581 shares during the last quarter. Finally, Segall Bryant & Hamill LLC increased its holdings in Ingevity by 8.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,287,281 shares of the company's stock valued at $52,457,000 after buying an additional 101,866 shares during the last quarter. Institutional investors own 91.59% of the company's stock.

Ingevity Stock Performance

Shares of NYSE NGVT traded up $0.85 during mid-day trading on Thursday, reaching $40.08. 55,897 shares of the company's stock were exchanged, compared to its average volume of 276,330. Ingevity Co. has a 52 week low of $28.49 and a 52 week high of $56.28. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -3.39 and a beta of 1.31. The firm has a 50-day moving average price of $37.67 and a two-hundred day moving average price of $41.73. The company has a debt-to-equity ratio of 6.86, a current ratio of 1.87 and a quick ratio of 1.04.

Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.25. The company had revenue of $284.00 million for the quarter, compared to the consensus estimate of $299.13 million. Ingevity had a negative net margin of 30.60% and a positive return on equity of 41.44%. Ingevity's quarterly revenue was down 16.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. Analysts predict that Ingevity Co. will post 4.45 EPS for the current year.

Wall Street Analyst Weigh In

NGVT has been the topic of several research reports. StockNews.com cut Ingevity from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Wells Fargo & Company increased their price objective on shares of Ingevity from $32.00 to $38.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, BMO Capital Markets raised shares of Ingevity from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $62.00 to $65.00 in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Ingevity presently has an average rating of "Moderate Buy" and an average target price of $52.75.

View Our Latest Stock Analysis on NGVT

About Ingevity

(Free Report)

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

Read More

Institutional Ownership by Quarter for Ingevity (NYSE:NGVT)

Should You Invest $1,000 in Ingevity Right Now?

Before you consider Ingevity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.

While Ingevity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant
NVIDIA Earnings Preview: HUGE Stock Move Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines